TrialProceedings of the National Academy of Sciences of the United States of America2023

Nasal administration of anti-CD3 mAb (Foralumab) downregulates

Thais G Moreira et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.